Navigation Links
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
Date:11/12/2008

SOUTH SAN FRANCISCO, Calif., Nov. 12 /PRNewswire/ -- Hyperion Therapeutics, Inc. today reported completion of data analysis for its Phase 2 clinical trial designed to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 versus BUPHENYL(R) (sodium phenylbutyrate), the current standard of care in patients with urea cycle disorders. Data from the trial will be presented at an upcoming medical conference.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

"We are encouraged by this trial and the potential to develop a new therapy for patients with urea cycle disorders," said Dr. Bruce Scharschmidt, Senior Vice President and Chief Medical Officer of Hyperion Therapeutics, Inc. "Based on the results, we plan to meet with the Food and Drug Administration in early 2009 to discuss our Phase 3 development program."

"We are pleased with the progress of the HPN-100 clinical program," said Cindy LeMons, Executive Director of the National Urea Cycle Disorders Foundation (NUCDF). "The urea cycle disorder community encourages the development of treatment alternatives."

Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 in August 2007. Under the terms of the agreement, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia.

About Urea Cycle Disorder

Urea cycle disorders are inherited, inborn errors of metabolism present in an estimated 1 in 10,000 births in the United States. Patients with urea cycle disorders are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. Onset may occur at any age depending on the severity of the disorder.
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
2. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
3. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
4. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
5. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
6. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Cornerstone Therapeutics Announces New Board of Directors
9. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
10. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
11. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... A study at the University of South Florida ... blood (MNChUCB) cells may help patients suffering from Amyotrophic ... A disease in which the motor neurons in the ... with progressive muscle weakness, paralysis and, finally, respiratory failure ...
... Caps Moves Forward, ALEXANDRIA, Va., June 24 ... passage of the Medicare,Improvements for Patients and Providers ... as a significant step forward for seniors and ... quickly follow suit., HR 6331 includes provisions ...
... 24 The following is a,statement by Robert D. ... members of The Kidney Care Council (KCC) applaud the ... the Medicare,Improvements for Patients and Providers Act of 2008, ... House of Representatives., "This legislation contains significant and ...
... of the fact that the intestines have a separate ... at the Kimmel Cancer Center at Jefferson in Philadelphia ... development of metastatic disease. , Reporting online Tuesday, ... National Cancer Institute , Scott Waldman, M.D., Ph.D., professor ...
... of Provisions for African American,Dialysis Patients, ... Jones released this statement regarding the Medicare,Improvements ... This legislation,prevents the pending 10 percent payment ... and mental health benefits, improves,and extends programs ...
... 24 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... announces the resignation of Executive Vice President,of Finance ... J.,Celebrezze has been named interim Chief Financial Officer, ... 2007, Mr. Celebrezze has served on the,Executive Management ...
Cached Medicine News:Health News:Umbilical cord blood cell transplants may help ALS patients 2Health News:Physical Therapists Applaud House Passage of Medicare Package 2Health News:The KCC Applauds House Action on ESRD Reform 2Health News:Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show 2Health News:Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show 3Health News:Tubbs Jones Supports Medicare Improvements Bill 2Health News:LCA-Vision Announces CFO Change 2
(Date:12/24/2014)... Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) today announced ... transaction on Tuesday to help fund the expansion and consolidation ... Sharon . PHN is ... Pennsylvania . It is the largest employer in ... 150 people on staff. Currently, PHN Sharon offers ...
(Date:12/24/2014)... DIEGO , Dec. 24, 2014  Conkwest, ... West, developing the proprietary Natural Killer (NK) cell-line ... that Dr. Patrick Soon-Shiong , NantWorks founder, ... a definitive agreement to purchase approximately $48 million ... connection with the investment, he will be named ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... at More Than 100 Sites in the U.S., ... Pharmaceuticals, a,privately-held biopharmaceutical company focused on development and,commercialization ... today announced that it has initiated a second,Phase ... company,s,estrogen-free oral therapy in development for the treatment ...
... Schedule with Two Abstracts Accepted for ... in November 2008, BRIDGEWATER, N.J., Sept. 4 ... on the treatment of,cardiovascular and metabolic disease, today ... the Company,s board of directors., Peter Garrambone,s ...
Cached Medicine Technology:QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: